Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(10):e46207.
doi: 10.1371/journal.pone.0046207. Epub 2012 Oct 4.

Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum

Affiliations

Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum

Stefan Röpcke et al. PLoS One. 2012.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory disease, primarily affecting the airways. Stable biomarkers characterizing the inflammatory phenotype of the disease, relevant for disease activity and suited to predict disease progression are needed to monitor the efficacy and safety of drug interventions. We therefore analyzed a large panel of markers in bronchoalveolar lavage, bronchial biopsies, serum and induced sputum of 23 healthy smokers and 24 smoking COPD patients (GOLD II) matched for age and gender. Sample collection was performed twice within a period of 6 weeks. Assays for over 100 different markers were validated for the respective matrices prior to analysis. In our study, we found 51 markers with a sufficient repeatability (intraclass correlation coefficient >0.6), most of these in serum. Differences between groups were observed for markers from all compartments, which extends (von-Willebrand-factor) and confirms (e.g. C-reactive-protein, interleukin-6) previous findings. No correlations between lung and serum markers were observed, including A1AT. Airway inflammation defined by sputum neutrophils showed only a moderate repeatability. This could be improved, when a combination of neutrophils and four sputum fluid phase markers was used to define the inflammatory phenotype.In summary, our study provides comprehensive information on the repeatability and interrelationship of pulmonary and systemic COPD-related markers. These results are relevant for ongoing large clinical trials and future COPD research. While serum markers can discriminate between smokers with and without COPD, they do not seem to sufficiently reflect the disease-associated inflammatory processes within the airways.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The study was performed at Fraunhofer ITEM in Hannover. Fraunhofer ITEM has received a grant from Nycomed GmbH for performing the study. The samples obtained from the subjects in this study were partly analysed at Fraunhofer ITEM, partly by Nycomed GmbH. The data analysis was performed by Dr P Ernst, Genedata AG, Dr S Roepcke, Dr G Lauer from Nycomed as well as by Dr O Holz and JM Hohlfeld from Fraunhofer ITEM. N.Krug, JM. Hohlfeld and O. Holz are employed at Fraunhofer ITEM and in addition participate in the Group of “Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), which is a member of the German Center for Lung Research. All authors of this manuscript declare not to have a competing interest with respect to the results of this study. Neither the cooperation and involvement in performing this study by Fraunhofer ITEM, Nycomed GmbH and Genedata AG, nor the participation in the German Center of Lung Research alters the adherence to all the PLOS ONE policies on sharing data and materials. Nycomed, Genedata and the Fraunhofer ITEM (this includes those authors of Fraunhofer ITEM) who additionally participate in the German center of lung research) are fully aware of and agree to the publishing policies of PlOS ONE.

Figures

Figure 1
Figure 1. Selected correlations between visits.
Correlation between samples collected in 2 visits within a time period of up to 6 weeks. The figure shows selected cellular biomarkers (A–D) and pro-inflammatory cytokines (E–H) from serum, BAL and ISP and examples for proteases (J, K), a glycoprotein and a growth-factor (I, L). The line of identity is displayed in all individual graphs. Data is displayed on log scales. The range of concentrations for each selected marker can be found in table 4 and in the tables of the online supplement. Filled symbols: COPD smokers, open symbols: healthy smokers.
Figure 2
Figure 2. Inflammatory phenotype.
Comparison between visits for the scores of the inflammatory phenotype, which were derived from a combination of repeatable sputum fluid phase markers (A1AT, IL6, MMP7, HSA and sputum neutrophils). This combined score shows a better correlation between visits (r = 0.70, p<0.001) as compared to sputum neutrophils alone (see figure 2C).
Figure 3
Figure 3. Study design.
Blood refers to the sample that was used for hematology and blood chemistry. Serum refers to the sample that was used for biomarker analysis. d = day.

References

    1. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, et al. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416–469. - PubMed
    1. Petty TL (2002) COPD in perspective. Chest 121: 116S–120S. - PubMed
    1. Crapo JD (2010) Preclinical vascular disease identifies smokers at risk for COPD. Proc Natl Acad Sci U S A 107: 8503–8504. - PMC - PubMed
    1. Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, et al. (2008) Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 178: 1211–1218. - PubMed
    1. [Anonymous] (2010) From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. -Available: http://www.goldcopd.com/. Accessed: September 6th, 2012).

Publication types

MeSH terms